Stocks Health care DMRA
NASDAQ · Health careDamora Therapeutics, Inc. (DMRA)
It posted a net loss of $291.7M. At September 30, 2026 it held $349.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Damora Therapeutics, Inc.
- Net worth
- Damora Therapeutics, Inc. has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $495.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $6.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Damora Therapeutics, Inc.'s next report is expected around March 18, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Damora Therapeutics, Inc. does
Damora Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker DMRA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$209.8M | $3.98 | n/a |
| 2024 | n/a | -$21.4M | -$18.53 | n/a |
| 2023 | n/a | -$38.3M | -$36.08 | n/a |
| 2022 | n/a | -$61.6M | -$60.89 | -$43.1M |
| 2021 | n/a | -$51.8M | -$51.36 | -$52.5M |
| 2020 | n/a | -$34.8M | -$190.92 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Damora Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026
- August 10, 2026Form S-8 POS filing S-8 POS
- August 10, 2026Form S-8 POS filing S-8 POS
- August 10, 2026Form POSASR filing POSASR
- August 10, 2026Form S-8 POS filing S-8 POS
- August 10, 2026Form S-8 POS filing S-8 POS
- August 10, 2026Form S-8 POS filing S-8 POS
- August 10, 2026Form S-8 POS filing S-8 POS
- August 10, 2026Form S-8 POS filing S-8 POS
- August 10, 2026Form S-8 POS filing S-8 POS
Insider trades
What the people running Damora Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $252.9K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 25, 2026 | Jarrett JenniferDirector, President and CEO, Director | Bought | 12,500 | $252.9K |
| July 6, 2026 | Winslow GarrettGeneral Counsel | Sold | 245 | $7.3K |
| July 3, 2026 | Winslow GarrettGeneral Counsel | Exercised options | 680 | - |
| March 30, 2026 | Jarrett JenniferSee Remarks, Director | Received as pay | 500,000 | - |
| February 9, 2026 | Fairmount Funds Management LLCDirector, 10% owner | Exercised optionsindirect | 5,809,000 | - |
| February 9, 2026 | Fairmount Funds Management LLCDirector, 10% owner | Exercised optionsindirect | 2,904,000 | - |
| February 9, 2026 | Bruno JulianneDirector | Exercised options | 129,000 | - |
| January 5, 2026 | Sattarzadeh SherwinChief Operating Officer | Received as pay | 190,376 | - |
Who owns DMRA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fairmount Funds Management LLC13D, may seek influence with 4 related filers | 19.99% | February 11, 2026 |
| Fmr LLC13G, passive with 1 related filers | 15% | December 5, 2025 |
| Avoro Capital Advisors LLC13G, passive with 1 related filers | 6.27% | May 15, 2026 |
| Venrock Healthcare Capital Partners III, L.P.13G, passive with 6 related filers | 6% | February 17, 2026 |
Largest institutional holders
Insiders
8 insiders reported holding 4,516,439 shares in total, about $109.9M at the last price.
| Holder | Shares |
|---|---|
| Fairmount Funds Management LLCDirector, 10% owner | 2,904,0002,904,000 held indirectly |
| Jarrett JenniferSee Remarks, Director | 1,012,500 |
| Hewes L. BeckerChief Medical Officer | 264,629 |
| Sattarzadeh SherwinChief Operating Officer | 190,376 |
| Bruno JulianneDirector | 137,032 |
| Schambye Hans T.Chief Executive Officer, Director | 4,682 |
| Winslow GarrettGeneral Counsel | 2,289 |
| Firmani LoriChief Financial Officer | 931 |
Questions about DMRA
What does Damora Therapeutics, Inc. do?
Damora Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as DMRA. Its shares trade on NASDAQ under the ticker DMRA.
What is Damora Therapeutics, Inc.'s net worth?
Damora Therapeutics, Inc. has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $495.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Damora Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $291.7M.
When did Damora Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Damora Therapeutics, Inc.'s next earnings report?
Damora Therapeutics, Inc.'s next report is expected around March 18, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare DMRA with
Follow DMRA
Get an email when Damora Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Damora Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.